Raymond James & Associates Voyager Therapeutics, Inc. Transaction History

Raymond James & Associates

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$4.94 - $6.61 $542,955 - $726,505	109,910 New	109,910 $670,000
Q1 2021 May 14, 2021	SELL	$4.61 - $9.04 $56,444 - $110,685	-12,244 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$7.15 - $12.28 $40,397 - $69,382	-5,650 Reduced 31.57%	12,244 $88,000
Q3 2020 Nov 04, 2020	BUY	$10.01 - $13.75 $11,431 - $15,702	1,142 Added 6.82%	17,894 $191,000
Q2 2020 Jul 28, 2020	BUY	$8.05 - $14.21 $5,296 - $9,350	658 Added 4.09%	16,752 $211,000
Q1 2020 Apr 21, 2020	BUY	$6.8 - $14.66 $12,389 - $26,710	1,822 Added 12.77%	16,094 $147,000
Q4 2019 Feb 12, 2020	SELL	$12.82 - $16.85 $154,404 - $202,941	-12,044 Reduced 45.77%	14,272 $199,000
Q3 2019 Nov 07, 2019	BUY	$16.31 - $28.29 $244,454 - $424,010	14,988 Added 132.31%	26,316 $453,000
Q2 2019 Aug 06, 2019	SELL	$19.18 - $27.88 $80,306 - $116,733	-4,187 Reduced 26.99%	11,328 $308,000
Q1 2019 May 06, 2019	BUY	$8.0 - $19.66 $124,120 - $305,024	15,515 New	15,515 $297,000

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $223M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.